Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TAAR1 | Q96RJ0 | 2/20 | 0.40 |
| ▸ | CHIT1 | Q13231 | 1/20 | 0.33 |
| ▸ | CHIA | Q9BZP6 | 1/20 | 0.33 |
| ▸ | SLC6A2 | P23975 | 3/20 | 0.33 |
| ▸ | SLC6A4 | P31645 | 3/20 | 0.33 |
| ▸ | SLC6A3 | Q01959 | 3/20 | 0.33 |
| ▸ | HTR1D | P28221 | 1/20 | 0.31 |
| ▸ | HTR1B | P28222 | 1/20 | 0.31 |
| ▸ | HRH3 | Q9Y5N1 | 1/20 | 0.30 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.30 |
| ▸ | KCNH2 | Q12809 | 1/20 | 0.30 |
| ▸ | AOC3 | Q16853 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL24366278 | 1.00 | TAAR1 (0.40) | TAAR1CHIT1CHIASLC6A2SLC6A4 | |
| SCHEMBL29343502 | 0.93 | SLC6A4 (0.36) | TAAR1SLC6A2SLC6A4SLC6A3 | |
| SCHEMBL24366408 | 0.80 | KDM4E (0.39) | CYP2D6 | |
| SCHEMBL24365618 | 0.79 | HRH3 (0.43) | TAAR1CHIT1CHIAHRH3 | |
| SCHEMBL24364832 | 0.79 | HRH3 (0.43) | TAAR1CHIT1CHIAHRH3 | |
| SCHEMBL30470625 | 0.78 | SLC6A2 (0.44) | SLC6A2SLC6A4SLC6A3CYP2D6KCNH2 | |
| SCHEMBL29325887 | 0.78 | SLC6A2 (0.44) | SLC6A2SLC6A4SLC6A3CYP2D6KCNH2 | |
| SCHEMBL29082001 | 0.78 | SLC6A2 (0.44) | SLC6A2SLC6A4SLC6A3CYP2D6KCNH2 | |
| SCHEMBL24364844 | 0.78 | MTNR1A (0.33) | — | |
| SCHEMBL24364264 | 0.77 | TAAR1 (0.43) | TAAR1HRH3AOC3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20240228478-A1 | COMPOUNDS AND METHODS OF USE | TANGO THERAPEUTICS, INC. | 2024-07-11 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20240228478-A1 | COMPOUNDS AND METHODS OF USE | F12, C1R, ABCG2 | TAAR1 555/4885CHIT1 2165/4885CHIA 4185/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.